Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Methylmalonic acidemia, also called methylmalonic aciduria, is defined in the packet as a genetically heterogeneous inherited disorder characterized by abnormalities in the metabolism of lipids and proteins. Signs and symptoms usually appear early in life and range from mild to life threatening. Listed subtypes include vitamin B12-responsive methylmalonic acidemia, mutase deficiency, cblD type, epimerase deficiency, transcobalamin receptor defect, combined malonic and methylmalonic acidemia, and methylmalonic aciduria with homocystinuria. The attached GeneReviews chapter is titled Isolated Methylmalonic Acidemia, so statements attributed to GeneReviews refer to the isolated forms. GeneReviews reports birth prevalence estimates of approximately 1 in 80,000 newborns for symptomatic methylmalonic aciduria in Quebec urine screening, an aggregate incidence of 1 in 159,614 across United States newborn screening programs, and a meta-analysis detection rate of 1 in 100,000 in North America, Europe and Asia-Pacific, with higher rates in the Middle East, North Africa and Japan. These figures are regional or program-based, not worldwide prevalence.
The packet definition lists vomiting, dehydration, hypotonia, developmental delays, hepatomegaly, lethargy, intellectual disabilities and chronic kidney disease, usually beginning early in life. Structured phenotype and age-of-onset fields are not populated. GeneReviews describes the isolated forms as periods of relative health interrupted by metabolic decompensation, usually associated with infections and stress, each of which can be life threatening. The mut0 form is described as the most common severe form, typically presenting in infancy. The mut-minus form may present later, with feeding problems, failure to thrive, hypotonia and developmental delay, and some individuals have renal tubular acidosis or chronic renal failure as the primary finding. The cblB form is described as usually resembling mut0, the cblA form as B12-responsive, and the cblD form as associated with metabolic acidosis, respiratory distress, hyperammonemia and neurologic symptoms. Epimerase deficiency is described as generally milder, ranging from no symptoms to severe metabolic acidosis.
The structured gene field is empty in the packet and no structured inheritance pattern is recorded. The attached GeneReviews chapter attributes the isolated forms to variants in MMUT, MMAA, MMAB, MCEE and MMADHC, so the condition can result from variants in several different genes, and a single mechanism is not stated to apply to all forms. It describes the biochemical defect as failure to convert methylmalonyl-CoA into succinyl-CoA during propionyl-CoA metabolism in the mitochondrial matrix. GeneReviews states that all forms of isolated methylmalonic acidemia are inherited in an autosomal recessive manner, and that heterozygous carriers have normal metabolite concentrations. It also states that precise genotype-phenotype correlations are difficult to determine because most affected individuals are compound heterozygous and many pathogenic variants are not recurrent. The genetic basis of combined forms listed as subtypes is not separately certified in this packet.
Diagnostic information in this packet comes from the GeneReviews diagnosis chapter. Newborn screening for isolated forms is described as primarily based on propionylcarnitine (C3) on dried blood spots, with cutoffs set by individual state programs. GeneReviews notes that propionylcarnitine is among the analytes most often responsible for false positives and that ratios such as C3/C2 and C3/methionine are used with elevated C3. A positive result is described as followed by testing for methylmalonic acid, 2-methylcitrate and total homocysteine to distinguish isolated forms from propionic acidemia and from combined methylmalonic acidemia with homocystinuria. Follow-up biochemical testing typically shows elevated plasma and urine methylmalonic acid, characteristic urine organic acids, elevated glycine, elevated propionylcarnitine, and normal serum B12 and plasma homocysteine. Elevated ammonia, ketoacidosis and hypoglycemia are described in some cases. GeneReviews also presents a differential diagnosis of other disorders with elevated methylmalonic acid and notes that combined malonic and methylmalonic aciduria is not detected by dried blood spot acylcarnitine screening. Molecular testing details are not certified in this packet.
No FDA-approved therapies are recorded in this packet. Several orphan drug designations, all with status DESIGNATED, are listed, which indicates designation and not marketing approval. They include hydroxocobalamin, hydroxocobalamin with methylcobalamin, 2,2-dimethylbutanoic acid, and several gene-therapy constructs using lentiviral or adeno-associated virus 9 vectors. GeneReviews describes management of isolated forms as multidisciplinary with oversight from a specialized metabolic center, referring to consensus guidelines published in 2014 and revised in 2021. Routine management described includes hydroxocobalamin supplementation in individuals known to be B12 responsive, natural protein restriction with a high-calorie diet and medical foods, feeding interventions such as gastrostomy for feeding difficulties and growth failure, carnitine supplementation for secondary carnitine deficiency, and cyclic antibiotic therapy to reduce gut propionate production, which GeneReviews notes carries its own risks. GeneReviews also lists fasting, stress, increased dietary protein, individual valine and isoleucine supplementation, nephrotoxic agents and QTc-prolonging agents as unfavorable circumstances. Dosing details are not reproduced here.
10 trials found
The following describes groups as reported in GeneReviews and not individuals. The natural history is described as periods of relative health with intermittent decompensation that can be life threatening. The mut0 form is described as having higher mortality and neurologic and multisystem complications than the mut-minus and cblA forms, with renal disease in approximately 43 to 60 percent and a median onset of 6 to 11 years. In the cblB form, chronic renal failure is described in approximately 66 percent. For the B12-responsive cblA form, GeneReviews describes a milder course, normal life expectancy, and chronic renal failure in 9 to 12 percent when diagnosed early and consistently treated with injectable B12, and notes risk of significant neurologic and multiorgan complications when diet and B12 therapy are not followed. Individuals identified through expanded newborn screening are described as having decreased early mortality, less severe symptoms at diagnosis and lower incidence of movement disorders, although some infants with the mut0 subtype present before results are available.
GeneReviews describes a 13-C-propionate breath test as a surrogate biomarker of disease severity, and liver-targeted genomic therapies, including gene therapy, mRNA replacement and genome editing, as promising in animal models and reaching Phase I/II trials, with long-term clinical effects yet to be established. The packet lists eight active ClinicalTrials.gov records. NCT00078078 (National Human Genome Research Institute) is a clinical and laboratory study of methylmalonic acidemia, recruiting. NCT07432880 (Genespire Srl) is a prospective pediatric study in MMUT-related disease, recruiting. NCT03655223 (RTI International) is the Early Check expanded newborn screening study, active not recruiting. NCT05506254 (Alexion Pharmaceuticals) is a long-term follow-up of recipients of hLB-001 gene therapy, active not recruiting. NCT05295433 (ModernaTX) is a Phase 1 extension study of mRNA-3705, recruiting. NCT07163364 (CSPC ZhongQi) is a Phase 3 hydroxocobalamin study in combined methylmalonic acidemia cblC type, not yet recruiting. NCT05040178 and NCT04176523 (Recordati Group) are observational studies involving Carbaglu, both recruiting.
Data assembled from 5 of 12 sources · Last updated Nov 18, 2026, 8:20 AM UTC
Genetic and Rare Diseases Info Center
AI-curated news mentioning methylmalonic acidemia
Updated Jul 25, 2026
Recent research highlights methylmalonic acidemia as a reversible cause of pediatric pulmonary hypertension, previously misdiagnosed as idiopathic pulmonary arterial hypertension. This discovery could lead to improved diagnostic accuracy and treatment options for affected children.
A recent study utilizing whole exome sequencing has provided new insights into the clinical and genetic landscapes of methylmalonic acidemia (MMA) and cystathionine beta-synthase deficiency (CBS). This research enhances understanding of these rare metabolic disorders, potentially guiding future diagnostics and treatments.